Common antidepressant may ease long COVID’s crushing fatigue
A low-cost antidepressant may offer new hope for people struggling with long COVID fatigue. In a randomized clinical trial involving 399 adults, fluvoxamine significantly reduced fatigue and improved quality of life compared with a placebo, making it one of the first medications
The potential for fluvoxamine to alleviate long COVID fatigue is a significant development, particularly given the dearth of effective treatments for this condition. Long COVID, also known as post-acute COVID-19 syndrome (PACS), affects millions worldwide, with fatigue being one of its most debilitating symptoms. The fact that a low-cost antidepressant, already widely available, may offer relief is a welcome prospect for those struggling with this condition.
In the context of the ongoing pandemic, the search for effective treatments for long COVID has been a pressing concern. While vaccines have been instrumental in reducing severe illness and death, the lingering effects of COVID-19 on physical and mental health have become increasingly apparent. The mech community, focused on science and discovery, will be closely watching further research on fluvoxamine and its applications. As the study involved a sizable sample size and demonstrated notable improvements in quality of life, these findings warrant attention and further investigation.
To watch next: larger-scale trials to confirm the efficacy and safety of fluvoxamine for long COVID fatigue, as well as research into the underlying mechanisms of this condition and how fluvoxamine interacts with them. Additionally, the possibility of repurposing other existing medications to address long COVID symptoms will likely continue to be explored. As the understanding of COVID-19 and its long-term effects evolves, staying abreast of emerging treatments and research will be crucial for the mech community and those affected by long COVID.
Originally reported by sciencedaily.com. MechNews adds analysis for science & discovery readers.